Live Breaking News & Updates on Treatment Response Definitions

Gilead-Kite Oncology demonstrate dedication to advancing research for hard-to-treat blood cancers at 26th Annual Meeting of the European Hematology Association (EHA) Primary results of pivotal ZUMA-3 trial, including pre-specified patient reported outcomes (PRO) in adult patients with relapsed/refractory acute lymph. ....

Axicabtagene Ciloleucel , Dominique Tonelli , Olalekano Oluwole , Health Economics , Outcomes Research , Study Name , Acute Lymphoblastic Leukemia , Antigen Receptor , T Cell Therapy , Adult Patients , Refractoryb Cell Acute Lymphoblastic Leukemia , Non Hodgkin Lymphoma , Refractory Indolent Non Hodgkin Lymphoma , High Risk Feature , Diffuse Largeb Cell Lymphoma , Refractory Largeb Cell Lymphoma , Mantle Cell Lymphoma , Refractory Mantle Cell Lymphoma , Term Results , Antigen Receptort Cell Therapy , Adolescent Patients , Refractoryb Cell Acute Lymphoblastic , Effectiveness Analysis , Bruton Tyrosine Kinase Inhibitors , Real World Evidence , Treatment Response Definitions ,